HanAll Biopharma has entered into a strategic collaboration and licence agreement with Harbour BioMed for the development, manufacturing and commercialization of two of HanAll's novel biologics in Greater China (including Hong Kong, Macau and Taiwan). The biologics include the anti-FcRn monoclonal antibody, HL161, for the treatment of pathogenic igG-mediated autoimmune diseases, and the anti-TNF ophthalmic solution, HL036, for dry eye and other inflammatory diseases. Under the terms of the agreement, HanAll will receive up to USD 81 million in total upfront, development, registration and sales milestones, as well as royalties on net sales. HanAll will continue to have the rights outside of Greater China.